<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624481</url>
  </required_header>
  <id_info>
    <org_study_id>C07-008</org_study_id>
    <nct_id>NCT00624481</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD</brief_title>
  <official_title>A Phase 2, 24-Week, Multicenter, Randomized, Parallel-Group, Dose-Ranging Study To Evaluate The Effect Of Teriparatide Nasal Spray On Bone Mineral Density In Postmenopausal Women With Low Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nastech Pharmaceutical Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nastech Pharmaceutical Company, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to compare the effect of increasing nasal teriparatide dosing
      on percent change in Bone Mineral Density (BMD) of the lumbar spine after 24 weeks of therapy
      in postmenopausal women with low bone mineral density.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bone mineral density of the lumbar spine from baseline to 24 weeks post treatment.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density from baseline to 12 weeks post treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, including hypercalcemia and nasal effects</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bone markers PINP and CTX from baseline to 4, 12 and 24 weeks post treatment</measure>
    <time_frame>4, 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>20ug subcutaneous injection daily for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Forteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide Nasal Spray</intervention_name>
    <description>teriparatide intranasally daily for 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide Nasal Spray</intervention_name>
    <description>teriparatide intranasally daily for 24 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide Nasal Spray</intervention_name>
    <description>teriparatide intranasally daily for 24 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide Nasal Spray</intervention_name>
    <description>teriparatide intranasally daily for 24 weeks</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal Female patients up to 89 years, inclusive;

          -  BMI ≤ 35 kg/m2, inclusive;

          -  In good health, determined by medical history and physical examination, as well as
             normal 12-lead ECG and vital signs;

          -  Females will be non-pregnant, non-lactating, and either post-menopausal for at least 1
             year, surgically sterile (including tubal ligation, hysterectomy) for at least 3
             months, until 30 days following Study Completion be willing to use an approved method
             of contraception;

          -  Have a minimum of two evaluable non-fractured lumbar vertebrae.

          -  Have low bone mineral density defined as having a T-score ≤ -2.0 as determined by DXA
             scan at either the lumbar spine (L1-L4) or total hip

        Exclusion Criteria:

          -  Serious Medical Condition

          -  History of diseases which affect bone metabolism other than postmenopausal
             osteoporosis such as Paget's disease, any secondary causes of osteoporosis,
             hypoparathyroidism, or hyperparathyroidism

          -  Have a history of cancer within the past 5 years, except for basal cell carcinoma

          -  Have hypocalcemia or hypercalcemia from any cause or have a recent history of kidney
             stones or pre-existing hypercalciuria;

          -  Have used any of the mostly commonly prescribed osteoporosis medications within 3
             months of starting the investigational product, or for more than 1 month at any time
             within 6 months prior to starting investigational product.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Brandt, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nastech Pharmaceutical Company, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2008</study_first_posted>
  <last_update_submitted>March 11, 2008</last_update_submitted>
  <last_update_submitted_qc>March 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Nastech Pharmaceutical Company Inc. ( Gordon Brandt, M.D. / President )</name_title>
    <organization>Nastech Pharmaceutical Company Inc.</organization>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>osteopenia</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>teriparatide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

